107 related articles for article (PubMed ID: 20184613)
1. Borreliosis mimicking lupus-like syndrome during infliximab treatment.
Molin S; Ruzicka T; Prinz JC
Clin Exp Dermatol; 2010 Aug; 35(6):631-3. PubMed ID: 20184613
[TBL] [Abstract][Full Text] [Related]
2. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF-alpha-induced systemic lupus syndrome.
Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
[TBL] [Abstract][Full Text] [Related]
4. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
5. Infliximab-induced SLE-like syndrome involving the lung and pleura.
Diri E; Tello W; Ratnoff WD; Nugent K
Lupus; 2007; 16(9):764-6. PubMed ID: 17728373
[No Abstract] [Full Text] [Related]
6. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
7. Potential target of infliximab in autoimmune and inflammatory diseases.
Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
[TBL] [Abstract][Full Text] [Related]
8. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
9. Osteomyelitis occurring during infliximab treatment of severe psoriasis.
Sri JC; Tsai CL; Deng A; Gaspari AA
J Drugs Dermatol; 2007 Feb; 6(2):207-10. PubMed ID: 17373180
[TBL] [Abstract][Full Text] [Related]
10. Adverse skin reactions to infliximab in the treatment of intraocular inflammation.
Wegscheider BJ; El-Shabrawi L; Weger M; Ardjomand N; Hermann J; Aberer E; El-Shabrawi Y
Eye (Lond); 2007 Apr; 21(4):547-9. PubMed ID: 16456589
[TBL] [Abstract][Full Text] [Related]
11. [Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis].
Haake H; Köneke J; Amann K; vom Dahl J; Janssen U
Med Klin (Munich); 2007 Oct; 102(10):852-7. PubMed ID: 17928969
[TBL] [Abstract][Full Text] [Related]
12. [Drug-induced alveolitis associated with infliximab/azathioprine therapy].
El-Hag K; Dercken HG; Prenzel R; Hölzle E
Pneumologie; 2008 Apr; 62(4):204-8. PubMed ID: 18270925
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Aringer M; Graninger WB; Steiner G; Smolen JS
Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
[TBL] [Abstract][Full Text] [Related]
15. A lupus-like syndrome induced by infliximab treatment.
Liggi M; Gilli A; Lai MA; Francesca Boi M; Usai P
Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):685-7. PubMed ID: 21665563
[No Abstract] [Full Text] [Related]
16. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of infliximab in active SLE: a pilot study.
Uppal SS; Hayat SJ; Raghupathy R
Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
[TBL] [Abstract][Full Text] [Related]
18. Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab.
Havel J; Aboutalebi S; Doughty L; Wirges M
J Drugs Dermatol; 2008 Aug; 7(8):796-8. PubMed ID: 18720701
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune diseases induced by TNF-targeted therapies.
Ramos-Casals M; Brito-Zerón P; Soto MJ; Cuadrado MJ; Khamashta MA
Best Pract Res Clin Rheumatol; 2008 Oct; 22(5):847-61. PubMed ID: 19028367
[TBL] [Abstract][Full Text] [Related]
20. Sarcoidosis during infliximab therapy for Crohn's disease.
Takahashi H; Kaneta K; Honma M; Ishida-Yamamoto A; Ashida T; Kohgo Y; Ohsaki Y; Iizuka H
J Dermatol; 2010 May; 37(5):471-4. PubMed ID: 20536653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
